MindWalk Holdings Corp.
HYFT Healthcare Biotechnology
MindWalk Holdings Corp.’s revenue for fiscal 2026 (year ended April 2026) was $11.3 million, down 35.9% from fiscal 2025. In the quarter to July 2026, revenue grew 19.4%, EPS fell 80.0%, free cash flow grew 9.79% and total debt fell 10.8%, each against the same quarter a year earlier.
Follow HYFT
MindWalk Holdings Corp. (HYFT) P/E ratio
MindWalk Holdings Corp. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2026 | 0.0× | — |
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jul 2026 | 0.0× | — |
| Apr 2026 | 0.0× | — |
| Jan 2026 | 0.0× | — |
| Oct 2025 | 0.0× | — |
| 23 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CSBR Champions Oncology, Inc. compare | n/m |
| HYFT MindWalk Holdings Corp. | n/m |
| VRCA Verrica Pharmaceuticals Inc. compare | n/m |
| XBIT XBiotech Inc. compare | n/m |
| NMAD Nomad Power Solutions, Inc. compare | n/m |
| CING Cingulate Inc. compare | n/m |
| OSTX OS Therapies Incorporated compare | n/m |
| FBIO Fortress Biotech, Inc. compare | 0.6× |
| SPRO Spero Therapeutics, Inc. compare | 7.9× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)